Fujian Aonong Biological Technology Group Incorporation Limited (SHA:603363)
China
· Delayed Price · Currency is CNY 3.580
-0.110 (-2.98%)
Apr 28, 2025, 2:45 PM CST
SHA:603363 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 8,763 | 19,432 | 21,581 | 18,013 | 11,504 | Upgrade
|
| Other Revenue | - | 25.21 | 31.93 | 25.56 | 12.72 | Upgrade
|
| Revenue | 8,763 | 19,458 | 21,613 | 18,038 | 11,517 | Upgrade
|
| Revenue Growth (YoY) | -54.96% | -9.97% | 19.82% | 56.62% | 98.98% | Upgrade
|
| Cost of Revenue | 8,345 | 20,767 | 20,956 | 18,209 | 9,531 | Upgrade
|
| Gross Profit | 417.42 | -1,309 | 657.28 | -170.49 | 1,986 | Upgrade
|
| Selling, General & Admin | - | 1,071 | 1,073 | 944.98 | 677.96 | Upgrade
|
| Research & Development | - | 148.86 | 161.67 | 113.88 | 65.36 | Upgrade
|
| Other Operating Expenses | - | 24.6 | 25.76 | -2.41 | 16.78 | Upgrade
|
| Operating Expenses | - | 1,291 | 1,285 | 1,101 | 822.49 | Upgrade
|
| Operating Income | 417.42 | -2,600 | -628.17 | -1,272 | 1,163 | Upgrade
|
| Interest Expense | - | -549.99 | -505.83 | -418.77 | -177.15 | Upgrade
|
| Interest & Investment Income | - | 5.19 | 5.94 | 3.76 | 9.74 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -1.41 | -6.85 | -0.34 | 0.05 | Upgrade
|
| Other Non Operating Income (Expenses) | -332.93 | -52.18 | -75.77 | -20.85 | -40.51 | Upgrade
|
| EBT Excluding Unusual Items | 84.49 | -3,198 | -1,211 | -1,708 | 955.48 | Upgrade
|
| Impairment of Goodwill | - | -34.66 | -36.51 | -12.14 | -4.31 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -4.07 | -119.76 | -68.86 | -23.69 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -49.74 | -9.41 | -25.09 | -15.46 | Upgrade
|
| Asset Writedown | - | -424.3 | -2.76 | -7.63 | - | Upgrade
|
| Other Unusual Items | - | 29.37 | 84.1 | - | 58.49 | Upgrade
|
| Pretax Income | 84.49 | -3,682 | -1,295 | -1,822 | 970.52 | Upgrade
|
| Income Tax Expense | -494.85 | 87.05 | -69.21 | 29.34 | -23.09 | Upgrade
|
| Earnings From Continuing Operations | 579.35 | -3,769 | -1,226 | -1,851 | 993.61 | Upgrade
|
| Minority Interest in Earnings | - | 117.86 | 187.46 | 331.05 | -420.62 | Upgrade
|
| Net Income | 579.35 | -3,651 | -1,038 | -1,520 | 572.99 | Upgrade
|
| Net Income to Common | 579.35 | -3,651 | -1,038 | -1,520 | 572.99 | Upgrade
|
| Net Income Growth | - | - | - | - | 1865.27% | Upgrade
|
| Shares Outstanding (Basic) | 865 | 867 | 775 | 650 | 603 | Upgrade
|
| Shares Outstanding (Diluted) | 865 | 867 | 775 | 650 | 630 | Upgrade
|
| Shares Change (YoY) | -0.29% | 11.91% | 19.30% | 3.15% | 7.98% | Upgrade
|
| EPS (Basic) | 0.67 | -4.21 | -1.34 | -2.34 | 0.95 | Upgrade
|
| EPS (Diluted) | 0.67 | -4.21 | -1.34 | -2.34 | 0.91 | Upgrade
|
| EPS Growth | - | - | - | - | 1720.00% | Upgrade
|
| Free Cash Flow | - | 472.23 | -835.31 | -2,184 | -2,887 | Upgrade
|
| Free Cash Flow Per Share | - | 0.55 | -1.08 | -3.36 | -4.58 | Upgrade
|
| Dividend Per Share | - | - | - | - | 0.227 | Upgrade
|
| Gross Margin | 4.76% | -6.73% | 3.04% | -0.95% | 17.24% | Upgrade
|
| Operating Margin | 4.76% | -13.36% | -2.91% | -7.05% | 10.10% | Upgrade
|
| Profit Margin | 6.61% | -18.76% | -4.80% | -8.43% | 4.98% | Upgrade
|
| Free Cash Flow Margin | - | 2.43% | -3.86% | -12.11% | -25.06% | Upgrade
|
| EBITDA | 1,240 | -1,777 | 232.72 | -574.94 | 1,491 | Upgrade
|
| EBITDA Margin | 14.15% | -9.13% | 1.08% | -3.19% | 12.94% | Upgrade
|
| D&A For EBITDA | 822.6 | 822.6 | 860.9 | 696.72 | 327.21 | Upgrade
|
| EBIT | 417.42 | -2,600 | -628.17 | -1,272 | 1,163 | Upgrade
|
| EBIT Margin | 4.76% | -13.36% | -2.91% | -7.05% | 10.10% | Upgrade
|
| Revenue as Reported | - | 19,458 | 21,613 | 18,038 | 11,517 | Upgrade
|
Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.